Hyperhidrosis Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 656.72 Million |
| Market Size (2029) | USD 860.76 Million |
| CAGR (2024 - 2029) | 5.56 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Hyperhidrosis Treatment Market Analysis
The Hyperhidrosis Treatment Market size is estimated at USD 656.72 million in 2024, and is expected to reach USD 860.76 million by 2029, growing at a CAGR of 5.56% during the forecast period (2024-2029).
The pandemic has significantly impacted the market. For instance, as per the NCBI study published in January 2021, during the initial phase of the COVID-19 infection, the condition of most of the prolonged cases of hypothermia resulted in fever. Thus, the demand for hyperhidrosis treatment increased initially; however, the market also witnessed an adverse impact. According to the International Hyperhidrosis Society in May 2021, sweat could help prevent the transmission of COVID-19. The organization supports that claim with quotes from experts like dermatologist Adam Friedman of George Washington University, who noted that "Sweat has some inherent antimicrobial activity." Therefore, the market witnessed moderate growth during the initial days of the pandemic. However, with the declining cases of COVID-19, the market has started to gain momentum and is expected to witness an upward trend over the forecast period.
The key factors bolstering the growth of the hyperhidrosis treatment market are the rise in the prevalence of secondary hyperhidrosis conditions and the increase in investments in research and development by the market players. According to the NCBI study published in October 2021, in the United States, the prevalence rate of this disorder was estimated to be around 3.0% of the total population. Emotional, psychological, social, and occupational impairment can all be caused by hyperhidrosis.
Some other factors that could potentially impact the market's growth are the promising pipeline for hyperhidrosis treatment, the growing prevalence of depression and anxiety, growing awareness about hyperhidrosis, and the presence of favorable reimbursement policies. For instance, in October 2021, Brickell Biotech Inc. reported positive topline results from the Phase 3 pivotal Cardigan I and Cardigan II studies, which evaluated sofpironium bromide gel, 15% as a once-daily topical formulation in patients with primary axillary hyperhidrosis. Thus, the increasing burden of hyperhidrosis and treatment advancements are anticipated to bolster the demand for its treatment, thereby boosting the market's growth.
Geographical expansions, product launches, acquisitions, collaborations, mergers, and partnerships by major players to establish a strong presence positively impact the market. For instance, in April 2021, Fortress Biotech, the partner company of Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to these factors, the market studied is expected to witness growth over the forecast period.
However, short-term results of cosmetic and therapeutic procedures are likely to restrain the growth of the hyperhidrosis treatment market over the forecast period.
Hyperhidrosis Treatment Market Trends
Botulin Toxin A is Expected to Hold the Largest Market Share Over the Forecast Period
Botulinum toxin type A is a safe and effective treatment for focal hyperhidrosis that lasts longer than topical treatments and does not require invasive surgical procedures. Botulinum toxin injections are most commonly used to treat axillary hyperhidrosis, but they can also be used to treat palmar and plantar disease. Botulinum toxin's effects last six to nine months on average, and treatment is linked to a high satisfaction rate among patients.
AbbVie Inc. owns BOTOX, which is the most researched botulinum toxin in the world. BOTOX has been approved for the treatment of excessive sweating in the underarms in at least 20 countries. It can also be used off-label to treat sweating in the face, feet, and hands. In April 2021, Aquavit Holdings LLC announced that it acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in the United States and Canada. Excessive sweating of the armpits, hands, feet, head, and face (craniofacial) and other relatively small body areas (like under the breasts) can be treated with botulinum toxin A as per the article published by the International Hyperhidrosis Society in October 2020. Botox has been shown to reduce sweating by 82.0% to 87.0% when used to treat excessive sweating under the arms. The effects begin to show up two to four days after treatment, with the full effects usually appearing within two weeks. Dryness lasts four to 12 months on average, but some studies have found that it can last up to 14 months.
Various studies have demonstrated its efficacy in reducing anxiety as well. For instance, according to a study published in the journal Scientific Reports in 2021, people who received Botox injections at four different sites reported significantly fewer signs of anxiety than those who received different treatments for the same conditions. The risk of anxiety was found to be reduced by 22.0% to 72.0% in Botox patients. Hence, the effectiveness of botulinum toxin type A in treating hyperhidrosis and its long-lasting effect is driving the market's growth.
North America is Expected to Hold the Largest Market Share Over the Forecast Period
North America is expected to dominate the overall hyperhidrosis treatment market throughout the forecast period. The growth is owing to factors such as the increasing burden of primary hyperhidrosis, cancer, and cardiovascular disorders, increases in secondary hyperhidrosis, technological advancements, and the presence of key market players in the region.
The high prevalence of primary and secondary hyperhidrosis will increase the adoption of treatment in the region. According to the NCBI research paper published in October 2022, approximately 2.8% of the US population suffers from hyperhidrosis, which is common in patients between 20 to 60 years of age. The high prevalence has increased the adoption of various treatments, such as over-the-counter aluminum chloride hexahydrate 20.0% in the region. Such prevalence will increase the demand for product consumption, thereby increasing the market's growth.
Key product launches, high concentration of market players or manufacturer's presence, acquisition and partnerships among major players, and increasing research and development activities for hyperhidrosis treatment products in the United States will lead to higher adoption of these products. For instance, in April 2021, Fortress Biotech, a partner company of Journey Medicals, entered into a definitive agreement to acquire Qbrexza (glycopyrronium) in the United States from Dermira, a wholly-owned subsidiary of Eli Lilly. Thus, owing to the above-mentioned factors, the market is expected to witness considerable growth over the forecast period.
Hyperhidrosis Treatment Industry Overview
The hyperhidrosis treatment market is moderately competitive and consists of several major players. The prominent players in the market are AbbVie, Brickell Biotech, Eli Lilly and Company (Dermira), Advin Healthcare, and Dermavant Scienecs Inc. (Roivant Sci), among others. The companies operating in the market are focusing on R&D investments and fundraising activities to conduct clinical trials that lead to strong product pipelines.
Hyperhidrosis Treatment Market Leaders
-
AbbVie Inc.
-
Eli Lilly (Dermira)
-
Advin Health Care
-
Dermavant (Roivant Sciences)
-
Brickell Biotech Inc.
*Disclaimer: Major Players sorted in no particular order
Hyperhidrosis Treatment Market News
- October 2022: Candesant Biomedical launched the "SweatTech Initiative" to raise awareness about the significant impact of hyperhidrosis, provide information on how treatments have evolved over the decades, and demonstrate the ongoing need for more modern treatments.
- May 2022: Meruho launched Rapifort Wipes in Japan for the treatment of primary axillary hyperhidrosis. It was the first prescription wipe preparation in the country.
Hyperhidrosis Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rise in Prevalence of Secondary Hyperhidrosis Condition
- 4.2.2 Increase in Investments by Market Players in Research and Development
-
4.3 Market Restraints
- 4.3.1 Short-term Results of Cosmetic and Therapeutic Procedures
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Treatment Type
- 5.1.1 Topical Treatments
- 5.1.2 Surgical Treatments
- 5.1.3 Botulin toxin A
- 5.1.4 Iontophoresis
- 5.1.5 Laser Treatments
- 5.1.6 Other Treatment Types
-
5.2 By Disease Type
- 5.2.1 Primary Focal Hyperhidrosis
- 5.2.2 Secondary Generalized Hyperhidrosis
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc. (Allergan PLC)
- 6.1.2 Brickell Biotech Inc.
- 6.1.3 Eli Lilly and Company (Dermira)
- 6.1.4 1315 Capital (miraDry Inc.)
- 6.1.5 SweatBlock
- 6.1.6 Merz Pharma (Merz Aesthetics)
- 6.1.7 Dermavant Sciences Inc. (Roivant Sciences)
- 6.1.8 Advin Health Care
- 6.1.9 Dermadry Laboratories Inc.
- 6.1.10 Dermata Therapeutics Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityHyperhidrosis Treatment Industry Segmentation
Hyperhidrosis is a disorder where the patient experiences excessive sweating issues that are independent of environmental conditions and thermoregulatory requirements.
The hyperhidrosis treatment market is segmented by disease type (primary focal hyperhidrosis and secondary generalized hyperhidrosis), treatment type (topical treatments, disposable, surgical treatments, botulin toxin A, iontophoresis, laser treatments, and other treatment types), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers value (in USD million) for the above segments.
| By Treatment Type | Topical Treatments | |
| Surgical Treatments | ||
| Botulin toxin A | ||
| Iontophoresis | ||
| Laser Treatments | ||
| Other Treatment Types | ||
| By Disease Type | Primary Focal Hyperhidrosis | |
| Secondary Generalized Hyperhidrosis | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Hyperhidrosis Treatment Market Research FAQs
How big is the Hyperhidrosis Treatment Market?
The Hyperhidrosis Treatment Market size is expected to reach USD 656.72 million in 2024 and grow at a CAGR of 5.56% to reach USD 860.76 million by 2029.
What is the current Hyperhidrosis Treatment Market size?
In 2024, the Hyperhidrosis Treatment Market size is expected to reach USD 656.72 million.
Who are the key players in Hyperhidrosis Treatment Market?
AbbVie Inc., Eli Lilly (Dermira), Advin Health Care, Dermavant (Roivant Sciences) and Brickell Biotech Inc. are the major companies operating in the Hyperhidrosis Treatment Market.
Which is the fastest growing region in Hyperhidrosis Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Hyperhidrosis Treatment Market?
In 2024, the North America accounts for the largest market share in Hyperhidrosis Treatment Market.
What years does this Hyperhidrosis Treatment Market cover, and what was the market size in 2023?
In 2023, the Hyperhidrosis Treatment Market size was estimated at USD 620.21 million. The report covers the Hyperhidrosis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Hyperhidrosis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Hyperhidrosis Treatment Industry Report
The Global Hyperhidrosis Treatment Market Insights & Outlook report provides a comprehensive industry overview and market analysis of hyperhidrosis treatments. This report is segmented by disease type, including primary focal hyperhidrosis and secondary generalized hyperhidrosis, and by treatment type, covering topical treatments, disposable treatments, surgical treatments, Botulin Toxin A, iontophoresis, laser treatments, and other treatment types. The geographic segmentation includes North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
The report offers valuable market data and industry statistics, providing insights into market size and market value. It includes a detailed market forecast, analyzing the market growth and market trends over the forecast period. Additionally, the report highlights the market leaders and provides an industry outlook, discussing the industry trends and industry research.
This industry report is essential for understanding the market segmentation and market predictions. The report example and report PDF are available for download, offering a detailed market review and industry information. The report also discusses the growth rate and market outlook, providing a thorough market overview and industry analysis.
Research companies and industry reports indicate that the hyperhidrosis treatment market is poised for significant growth, driven by advancements in treatment options and increasing awareness. The report provides a comprehensive market analysis, including industry sales and market segmentation, offering a complete picture of the industry size and industry trends. The market forecast and market predictions are based on extensive industry research, ensuring accurate and reliable market data.
For those seeking detailed information on the hyperhidrosis treatment market, this report is an invaluable resource, offering insights into market growth, industry statistics, and market segmentation. The report PDF is available for download, providing a comprehensive overview of the market and industry outlook.
